The biodegradable nanomaterials exhibit promising potential for tumor immunotherapy due to their unique advantages including biodegradability, simple and cost-effective synthesis, and use of renewable resources, aligning with environmental and sustainable development goals.
Abstract
Immunotherapy has rapidly emerged as the new pillar of cancer treatment alongside surgery, radiotherapy and chemotherapy. However, existing immunotherapeutic approaches face significant limitations such as inefficient tumor-targeted drug delivery, poor cellular internalization and off-target effects, all of which lead to suboptimal therapeutic outcomes. Recent advances in nanotechnology have introduced nanomedicines as a promising solution to these challenges, which can precisely deliver immunomodulators, enhance antigen presentation, and increase T-cell infiltration as well as improve their targeting and safety, and thus powerfully enhance the therapeutic effect of tumor immunotherapy. Among numerous types of nanomedicines, biodegradable nanomaterials have recently received extensive attention for tumor immunotherapy due to their unique advantages including biodegradability, simple and cost-effective synthesis, and use of renewable resources, aligning with environmental and sustainable development goals. More importantly, many biodegradable nanomedicine platforms, such as liposomes, polymeric micelles and polymeric nanoparticles, have already entered clinical trials or received approval. Thus, the biodegradable nanomaterials exhibit promising potential for tumor immunotherapy. However, comprehensive reviews systematically summarizing the application of biodegradable nanomaterials for tumor immunotherapy are still rare. Herein, this review provides a detailed introduction to this field. Firstly, the general types of biodegradable nanomaterials for tumor immunotherapy are introduced. Secondly, the common mechanisms of tumor immunotherapy are elucidated. Thirdly, the basic research applications of biodegradable nanomedicine-mediated tumor immunotherapy are emphasized. Next, the clinical transformation prospects of biodegradable nanomaterials for tumor immunotherapy are highlighted. Furthermore, the potential impacts of degradation behaviors on the immune microenvironment are pointed out. Finally, the challenges and future outlooks are discussed.
Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low na...
Guan-Ran Wang, Kun Du, Di-Kai Sun et al.· Frontiers in Immunology· 0 citations
Novel NCs like microemulsions, vesicular (liposomes), and nanoparticular NCs are created and explored, which have unique improved penetration and retention in the tumour tissue.
Shalu Tiwari, Abhijeet Ojha, A. Singh et al.· Journal of Drug Delivery and...· 0 citations
This review critically summarizes recent developments in advanced nanocarriers for cancer therapy, emphasizing their design principles, therapeutic applications, clinical translation, and the key challenges influencing their future clinical adoption.
Aliya Rehmani, Palak Ghanshyam Rahangdale, Payal Dilip Meshram· Journal of Drug Delivery and...· 0 citations
This review paper provides an integrated and critical perspective on next-generation nanomedicine by connecting nanocarrier design with tumor-specific accumulation, intracellular trafficking, stimuli-responsive drug release, combination therapy and clinical translation.
Biswajit Mohanty, P. Saikia, Piyush Pandey et al.· Frontiers in Chemistry· 0 citations
This review systematically summarizes targeted nanomedicines constructed from mainstream carriers, including polymeric, metallic, and biomimetic nanoparticles, and discusses the future prospects of artificial intelligence-assisted optimization strategies for nanomedicine development.
Rui-Chao Li, Ze-Yuan Sun, Si-Nian Li et al.· International Journal of Pha...· 0 citations
Abstract Tumor immunotherapy has substantially advanced cancer treatment by activating or enhancing the antitumor immune response. However, tumor heterogeneity, the immunosuppressive tumor microenvironment (TME), and therapeutic resistance limit the efficacy of single-agent immunotherapy, making mechanistically complem...
Tian-Ying Sun, Chuang Liu, Jiang Zhu et al.· International Journal of Nan...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.